Narratives
about treatment and rates of disease often involve conversation around the role
sex plays in these statistics, including mortality and morbidity rates. Governments and private organizations spend considerable
amounts of money towards identifying and focusing research on diseases that
predominately affect one sex over another. For example, prostate and breast
cancer, found primarily in men and women respectively, receive significant
funding and generate considerable public interest.
Sociologically, sex refers to the
biologically determined aspect of an individual’s identity, while gender is
considered to be culturally or socially constructed. While the role that sex
plays in the dimorphism of these diseases is evident, gender’s role is far less
clear and researched. In a medical world where treatment paths are largely
determined by the patient, individuals must choose an option that they are most
comfortable with.2,4 In the case of prostate cancer, men are often
faced with impotence or other sexual deficiencies resulting from treatment.
Similarly, the focus on breast cancer treatment often stresses saving the
breasts rather than the woman herself. Decisions about how to proceed in the
treatment process in such cases can be heavily influenced by conceptions of
gender. For example, a man’s idea of masculinity may affect his choice to lose
sexual function.1 Treatment time with procedures such as
chemotherapy and radiation may be extended, despite the fact that radical
prostatectomy or other procedures that damage nerves may be more effective
in preventing mortality. However, these procedures damage sexual function,
making them less desirable for some men.
Additionally, gender plays a critical
role in how individuals experience coping strategies both during and following
treatment. Sharing of one’s personal feelings is considered by society to be a
feminine quality; therefore fewer men feel comfortable participating in group
sessions due to this stigma.4 Research suggests that gender, not sex perceptions play a role in these results. This is important because counseling or the ability to speak openly about personal psychosocial issues surrounding treatment has been associated with morbidity rates.2 Specifically, several studies have focused on psychiatric
morbidity rates of patients experiencing treatment and how counseling affects
these rates. One such study looking at mastectomy patients showed that
morbidity rates were significantly less in counseling patients than those in a
control group (12% to 39%).3
If the ultimate goal of medicine is to reduce morbidity and mortality rates, then consideration of gender before, during, and after treatment must be taken into account. Health professionals must be aware of gendered belief systems and speak with patients openly about ramifications of conforming to these societal notions. Individuals also must be made aware of their own gender perceptions in order to allow them to best select treatments. For example, a male undergoing prostate procedures may be driven by gendered expectations of masculinity towards certain treatment options. The idea of losing sexual ability often conflicts with a man’s idea of how masculinity is maintained. If he is not able to engage with his partner sexually, the ability to perform masculinity may be compromised. By making him aware of gendered notions of masculinity and clearly presenting why certain treatment options are stigmatized, procedures that decrease mortality and morbidity, rather than those that preserve notions of gender, may become more desirable. Ignoring gender in medical practice is a detriment the moral codes of the medical community as well. As I mentioned earlier, the institution of medicine is more concerned with saving what is considered important for masculinity or femininity, rather than what is necessary for the individual, both phsyically and emotionally. This is not simply an issue of intellectual discourse, but notably affects medicine at an economic and moral level. If we are to believe that medicine is concerned with reducing illness and death, then taking gender into account, rather than simply sex, is important to combating vital psychosocial effects related to the experience of disease.
If the ultimate goal of medicine is to reduce morbidity and mortality rates, then consideration of gender before, during, and after treatment must be taken into account. Health professionals must be aware of gendered belief systems and speak with patients openly about ramifications of conforming to these societal notions. Individuals also must be made aware of their own gender perceptions in order to allow them to best select treatments. For example, a male undergoing prostate procedures may be driven by gendered expectations of masculinity towards certain treatment options. The idea of losing sexual ability often conflicts with a man’s idea of how masculinity is maintained. If he is not able to engage with his partner sexually, the ability to perform masculinity may be compromised. By making him aware of gendered notions of masculinity and clearly presenting why certain treatment options are stigmatized, procedures that decrease mortality and morbidity, rather than those that preserve notions of gender, may become more desirable. Ignoring gender in medical practice is a detriment the moral codes of the medical community as well. As I mentioned earlier, the institution of medicine is more concerned with saving what is considered important for masculinity or femininity, rather than what is necessary for the individual, both phsyically and emotionally. This is not simply an issue of intellectual discourse, but notably affects medicine at an economic and moral level. If we are to believe that medicine is concerned with reducing illness and death, then taking gender into account, rather than simply sex, is important to combating vital psychosocial effects related to the experience of disease.
References
1.
Kiss A and Meryn S. Effect of sex and gender of psychosocial aspects of
prostate and breast cancer. BMJ. 2001: 323(7320): 1055-1058.
2. Krizek C, Roberts C, Ragan R, Ferrara JJ, Lord B. Gender and cancer support group participation. Cancer Pract. 1999:7:86–92.
3. Maguire P, Tait A, Brooke M, Thomas C, Sellwood R. Effect of counselling on the psychiatric morbidity associated with mastectomy. BMJ. 1980; 281:1454–1456.
2. Krizek C, Roberts C, Ragan R, Ferrara JJ, Lord B. Gender and cancer support group participation. Cancer Pract. 1999:7:86–92.
3. Maguire P, Tait A, Brooke M, Thomas C, Sellwood R. Effect of counselling on the psychiatric morbidity associated with mastectomy. BMJ. 1980; 281:1454–1456.
4.
Volkers N. In coping with cancer, gender matters. J Natl Cancer Inst. 1999:91:1712-1714.